RU93051537A - Перорально вводимая лекарственная форма - Google Patents

Перорально вводимая лекарственная форма

Info

Publication number
RU93051537A
RU93051537A RU93051537/14A RU93051537A RU93051537A RU 93051537 A RU93051537 A RU 93051537A RU 93051537/14 A RU93051537/14 A RU 93051537/14A RU 93051537 A RU93051537 A RU 93051537A RU 93051537 A RU93051537 A RU 93051537A
Authority
RU
Russia
Prior art keywords
dosage form
oral dosage
carbidopa
levodopa
drugs
Prior art date
Application number
RU93051537/14A
Other languages
English (en)
Other versions
RU2114619C1 (ru
Inventor
Венцель Удо
Вебер Гюнтер
Метцнер Юрген
Дэрр Альфред
Фрайтаг Сабине
Флетер Франк-Ульрих
Альберт Франк-Михаель
Хаазе Маргит
Ляйстнер Эдит
Original Assignee
Изис Фарма ГмбХ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4101873A external-priority patent/DE4101873C2/de
Application filed by Изис Фарма ГмбХ filed Critical Изис Фарма ГмбХ
Publication of RU93051537A publication Critical patent/RU93051537A/ru
Application granted granted Critical
Publication of RU2114619C1 publication Critical patent/RU2114619C1/ru

Links

Claims (1)

  1. Перорально вводимая лекарственная форма содержит комбинацию лекарственных веществ леводопа и карбидопа в определенных соотношениях для лечения центральных состояний дефицита допамина.
RU93051537/14A 1991-01-23 1992-01-23 Перорально вводимая лекарственная форма RU2114619C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4101873A DE4101873C2 (de) 1991-01-23 1991-01-23 Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
DEP4101873.7 1991-01-23

Publications (2)

Publication Number Publication Date
RU93051537A true RU93051537A (ru) 1996-09-20
RU2114619C1 RU2114619C1 (ru) 1998-07-10

Family

ID=6423528

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93051537/14A RU2114619C1 (ru) 1991-01-23 1992-01-23 Перорально вводимая лекарственная форма

Country Status (22)

Country Link
US (1) US5532274A (ru)
EP (1) EP0568577B1 (ru)
JP (1) JP3382940B2 (ru)
AT (1) ATE147264T1 (ru)
AU (1) AU658171B2 (ru)
BG (1) BG61677B1 (ru)
CA (1) CA2101164C (ru)
CZ (1) CZ280847B6 (ru)
DE (2) DE4101873C2 (ru)
DK (1) DK0568577T3 (ru)
EE (1) EE03016B1 (ru)
ES (1) ES2098496T3 (ru)
FI (1) FI101040B (ru)
GR (1) GR3022993T3 (ru)
LT (1) LT3659B (ru)
LV (1) LV11103B (ru)
NO (1) NO304638B1 (ru)
RO (1) RO114737B1 (ru)
RU (1) RU2114619C1 (ru)
SK (1) SK369292A3 (ru)
UA (1) UA27848C2 (ru)
WO (1) WO1992012710A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756056B2 (en) * 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
CN1596100A (zh) * 2001-09-28 2005-03-16 麦克内尔-Ppc股份有限公司 可食用组合物及含可食用外壳的制剂
CA2501345A1 (en) * 2002-10-11 2004-04-22 Depomed Development, Ltd. Gastro-retentive levodopa delivery form
US8815950B2 (en) * 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
ATE495739T1 (de) 2003-08-29 2011-02-15 Transform Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ES2360759T3 (es) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
NZ560826A (en) * 2005-03-28 2009-06-26 Orexo Ab Composition comprising weak acid and particulate L-dopa useful in the treatment of parkinson's disease
WO2007002516A2 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
US20070275060A1 (en) * 2005-08-05 2007-11-29 Osmotica Costa Rica Sociedad Anonima Extended release solid pharmaceutical composition containing carbidopa and levodopa
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008079404A2 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2009085306A1 (en) 2007-12-28 2009-07-09 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
EP2233131A1 (en) * 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
KR20130009553A (ko) * 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
EP3782614A1 (en) 2013-10-07 2021-02-24 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
JP6695013B1 (ja) * 2018-11-13 2020-05-20 日本酢ビ・ポバール株式会社 結合剤
EP3881839A4 (en) * 2018-11-13 2022-08-24 Japan Vam & Poval Co., Ltd. BINDER
US20210395507A1 (en) * 2018-11-13 2021-12-23 Japan Vam & Poval Co., Ltd. Binder
EP3881838A4 (en) * 2018-11-13 2022-08-17 Japan Vam & Poval Co., Ltd. ADHESIVE
WO2021205886A1 (ja) * 2020-04-10 2021-10-14 日本酢ビ・ポバール株式会社 結合剤
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE631201C (de) * 1932-08-07 1936-06-16 Chemische Forschungs Gmbh Traegerstoff fuer Arzneimittel
DE748317C (de) * 1941-08-17 1944-12-19 Wacker Chemie Gmbh Verfahren zur Herstellung in Wasser zerfallender Faeden, Filme, Baender, Schlaeuche u. dgl. aus unvollstaendig verseiften Polyvinylalkoholen
US3584113A (en) * 1967-08-31 1971-06-08 Eisai Co Ltd Process for the production of medical preparations having sustained release of therapeutical effect
NL149372B (nl) * 1968-10-01 1976-05-17 Merck & Co Inc Werkwijze voor het bereiden van farmaceutische preparaten, alsmede de door toepassing daarvan verkregen gevormde voortbrengselen.
US3769424A (en) * 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
IE49522B1 (en) 1979-04-26 1985-10-16 Merrell Toraude & Co Alpha-halomethylaminoacids
DE3042916A1 (de) * 1979-06-01 1982-07-01 Joachim 7440 Nürtingen Dudzik Tablette
CA1218604A (en) * 1981-07-08 1987-03-03 Alec D. Keith Trinitroglycerol sustained release vehicles and preparations therefrom
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
CH652025A5 (de) 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
EP0147780A3 (en) * 1984-01-03 1987-03-11 Merck & Co. Inc. Drug delivery device
US4927633A (en) * 1984-03-19 1990-05-22 Alza Corporation Dispenser for delivering drug to livestock
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
ZA889189B (en) * 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US4940465A (en) * 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US4892778A (en) * 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
CA1331563C (en) * 1987-08-03 1994-08-23 Gaylen M. Zentner Device for the controlled release of drugs with donnan-like modulation by charged insoluble resins
AU608891B2 (en) * 1987-09-24 1991-04-18 Merck & Co., Inc. Solubility modulated drug delivery device
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
DE3875716D1 (de) * 1987-12-31 1992-12-10 Asta Medica Ag Synergistische kombination von decarboxylasehemmern und l-dopa-pellets.
DE3841955A1 (de) * 1987-12-31 1989-07-13 Asta Pharma Ag Synergistische kombination von decarboxylasehemmern und l-dopa-pellets

Similar Documents

Publication Publication Date Title
RU93051537A (ru) Перорально вводимая лекарственная форма
TR200002207T1 (tr) Slekoksib bileşikleri.
DK1348429T3 (da) Smelteekstruderede opioidformuleringer, der kan administreres oralt
GR3017891T3 (en) Dosage form for delivering drug in short-time period.
EA199600028A3 (ru) Оральная фармацевтическая композиция, содержащая s (+)-ибупрофен, и способ её получения
DE69002198D1 (de) Schnelloesliche dosierungsformen.
NZ236797A (en) Topical compositions comprising ibuprofen (or s-ibuprofen) dissolved in a hydroalcoholic gel having a ph of 3.5 to 6.0 and use thereof
CA2061917A1 (en) Pediatric effervescent dosage form
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
NO923859L (no) Medikament
SE9002500L (sv) Farmaceutisk, nac-innehaallande komposition foer oral administrering
CS545686A1 (en) Farmaceuticky prostredek a antihepatotoxickym pusobenim
IT1235153B (it) Uso dell'acetil l-carnitina nel trattamento terapeutico della cataratta e composizioni farmaceutiche utili in tale trattamento
ZA96576B (en) Extended-release solid oral dosage forms of drugs having low solubility in water
ES2026304A6 (es) Procedimiento de fabricacion de una forma de dosificacion de nicardipina.
FR2618331B1 (fr) Compositions pharmaceutiques utiles pour le traitement de l'uremie
FR2674754B1 (fr) Composition medicamenteuse micronisee.
DE69513767D1 (de) Pharmazeutische Zusammensetzung in Form eines Gels mit Chondroitinsulfat in Salzform zur oralen Verabreichung
IT1254314B (it) Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
ITRM920693A1 (it) Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hivsieropositivi.
IT1224250B (it) Associzione del depiprazolo con la morfina
ATE259778T1 (de) Nicht-hygroskopische salze aktiver inhaltsstoffe, die therapeutische und/oder ernährungsphysiologische eigenschaften haben und oral verabreichbare zusammensetzungen, die diese enthalten
RU93052408A (ru) Ациламино-алкилиден-гидрокси-бис-фосфоновые кислоты, способ их получения, фармацевтическая композиция
IL79207A (en) Geriatric pharmaceutical compositions containing terguride for treatment of cognitive and psychic disorders due to dopamine hypofunction
RU95105084A (ru) Гепатопротекторное средство природного происхождения